Appeal No. 96-3861
Application 08/114,251
hypertension as stated in the specification, paragraph bridging pages 8 and 9. We have
no doubt that the specification imparts adequate information to persons skilled in the art,
enabling them to make the claimed compounds and to use the claimed compounds as
antihypertensive agents if those compounds are useful for the stated purpose. Respecting
the "how-to-use" requirement of 35 U.S.C. § 112, first paragraph, the specification sets
forth in detail dosage ranges, modes of administration, and pharmaceutically acceptable
carriers, applicable for the claimed compounds. The specification also describes
numerous other compounds and agents which may be formulated with or useful in
conjunction with the claimed compounds.
Turning to the issue at hand, we find this statement in the specification, paragraph
bridging pages 8 and 9:
The compounds of formula 1 are antagonists of ET-1, ET-2, and/or ET-3
and are useful in treatment of all endothelin-dependent disorders. They are
thus useful as antihypertensive agents. By the administration of a
composition having one (or a combination) of the compounds of this
invention, the blood pressure of a hypertensive mammalian (e.g., human)
host is reduced.
According to Appellant, all of the claimed compounds are useful for treating hyper-tension,
i.e., for reducing blood pressure in a mammalian host.
3
Page: Previous 1 2 3 4 5 6 7 Next
Last modified: November 3, 2007